Clinical trials: Diabetic Neuropathy Peripheral
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Diabetic Foot
Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure
The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population. The main aims are: 1.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Foot, Peripheral Arterial Disease, Skin Cancer
- Trial name
- Spectrum1 (NCT06976073)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Diabetic Neuropathy, Painful, Diabetic Neuralgia
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200 mg of RWJ-333369 given twice daily by mouth compared with placebo in the treatment of Diabetic Peripheral Neuropathy (DPN).
- Conditions
- Diabetic Neuropathy, Painful, Diabetic Neuralgia, Diabetic Polyneuropathy, Diabetic Mononeuropathy
- Trial name
- NCT00501202
- Testing
- RWJ-333369 (carisbamate)
- Volunteers
- 132 people
- Sponsor
- SK Life Science, Inc.
Diabetic Neuropathies
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
- Trial name
- NCT04088929
- Testing
- CBD
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Pure Green
Diabetic Neuropathy, Painful
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to…
- Trial name
- NCT00385671
- Testing
- duloxetine hydrochloride, pregabalin, gabapentin
- Where
- 9 sites in United States, Germany
- Volunteers
- 407 people
- Sponsor
- Eli Lilly and Company
Painful Diabetic Neuropathy
Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy
This is a study investigating the effect of MEDI7352 on chronic pain in participants with painful diabetic neuropathy. The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or…
- Trial name
- NCT03755934
- Testing
- MEDI7352
- Where
- 31 sites in Denmark, Hungary and 3 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Neuralgia, Neuropathic Pain
Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management
Compare Axon Therapy plus conventional medical management (CMM) to Sham plus CMM in reducing neuropathic pain in patients with painful diabetic neuropathy (PDM).
- Conditions
- Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy
- Trial name
- NCT05620225
- Testing
- Axon Therapy and CMM
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- NeuraLace Medical, Inc.
Pain
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
The purpose of the study is to evaluate the efficacy and safety of OraVescent fentanyl treatment compared to placebo treatment monthly over a 12-week treatment period in alleviating breakthrough pain (BTP) in opioid-tolerant…
- Trial name
- NCT00343733
- Testing
- OraVescent Fentanyl
- Where
- 21 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon
Painful Diabetic Peripheral Neuropathy (PDPN)
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo.
- Trial name
- NCT02372578
- Testing
- ASP3662, pregabalin
- Where
- 37 sites in United States
- Volunteers
- 115 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Polyneuropathy, Diabetic
Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt
The purpose of the study is to find out whether ALA is effective and safe for treating Egyptian diabetic patients with symptomatic polyneuropathy.
- Trial name
- MIRACLE-ALA (NCT05813496)
- Testing
- Alpha-Lipoic Acid (ALA)
- Where
- 5 sites in Egypt
- Volunteers
- 430 people
- Sponsor
- Eva Pharma